Mga Batayang Estadistika
| CIK | 1761918 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Erasca, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2025 Registration No. |
|
| August 12, 2025 |
Exhibit 99.1 Erasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 12, 2025 |
EX-4.4 Exhibit 4.4 ERASCA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishm |
|
| August 12, 2025 |
EX-1.2 Exhibit 1.2 AMENDED AND RESTATED OPEN MARKET SALE AGREEMENTSM August 12, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Erasca, Inc., a Delaware corporation (the “Company”) and Jefferies LLC, as sales agent and/or principal (the “Agent”), are parties to that certain Open Market Sale AgreementSM dated August 11, 2022 (the “Original Agreement”) through wh |
|
| August 12, 2025 |
Calculation of Filing Fee Tables S-3 Erasca, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effect |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2025 |
Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2025 |
Non-Employee Director Compensation Program Exhibit 10.1 Erasca, Inc. Non-Employee Director Compensation Program Updated December 17, 2024 Non-employee members of the board of directors (the “Board”) of Erasca, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 29, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 20, 2025 |
Insider Trading Compliance Policy and Procedures Exhibit 19.1 Revised April 2023 Erasca, Inc. Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trad |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (E |
|
| March 20, 2025 |
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| February 13, 2025 |
Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| February 13, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| February 12, 2025 |
EVIDENCE OF SIGNATORY AUTHORITY EX-99.1 2 tm255748d2ex99-1.htm EXHIBIT 1 EXHIBIT 1 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled 1 CHE-106.052.527 Limited or Corporation 25.10.1989 All data In Ca Business name Ref Legal seat 1 Novartis Pharma AG 1 Basel 1 (Novartis Pharma SA) (Novartis Pharma Inc.) CHE-106.052.527 Novartis Pharma AG Basel |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 13, 2025 |
On a Journey to Erase Cancer Erasca Corporate Presentation January 2025 Eric N., naporafenib clinical trial participant and cancer survivor, and his wife Margaret Exhibit 99.1 We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operati |
|
| November 14, 2024 |
SC 13G/A 1 arch-sch13g18905.htm ARCH VENTURE FUND X, L.P. - ERASCA, INC. - SCH 13G/A(#1E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* Erasca, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 29479A108 (CUSIP Number) May 21, 2024 (Date of E |
|
| November 14, 2024 |
ERAS / Erasca, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-eras093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ERASCA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29479A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 12, 2024 |
Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, November 12, 2024 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| October 29, 2024 |
ERAS / Erasca, Inc. / City Hill, LLC - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 12, 2024 |
Erasca Reports Second Quarter 2024 Business Updates and Financial Results In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 registrational trial in patients with NRASm melanoma; randomized data for naporafenib plus trametinib vs. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 12, 2024 |
License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED LICENSE AGREEMENT This License Agreement (this “Agreement”) is made as of May 14, 2024 (the “Effective Date”), by and between Medshine Discovery Inc. (“Medshine”), a corporation duly organized an |
|
| August 12, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED LICENSE AGREEMENT This License Agreement (this “Agreement”) is made as of May 15, 2024 (the “Effective Date”), by and between Guangzhou Joyo Pharmatech Co., Ltd. (in Chinese, 广州嘉越医药科技有限公司), a cor |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 31, 2024 |
ERAS / Erasca, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 29479A108 (CUSIP Number) May 21, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| May 29, 2024 |
ERAS / Erasca, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 29, 2024 |
EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Erasca, Inc. Date: May 29, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By: FHMLSP, L.P., its General Par |
|
| May 28, 2024 |
ERAS / Erasca, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 17, 2024 |
Erasca Announces Pricing of Underwritten Offering of Common Stock EX-99.1 Exhibit 99.1 Erasca Announces Pricing of Underwritten Offering of Common Stock May 16, 2024 SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) – Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering |
|
| May 17, 2024 |
Exhibit 1.1 Erasca, Inc. 86,486,486 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement May 16, 2024 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: |
|
| May 17, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266802 Prospectus supplement (To prospectus dated August 18, 2022) 86,486,486 Shares Common stock We are offering 86,486,486 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ERAS.” On May 16, 2024, the last reported sale price for our common stock on the Nasdaq Global |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 16, 2024 |
EX-99.1 Exhibit 99.1 On a Journey to Erase Cancer Erasca Investor Update May 2024 Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business stra |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 14, 2024 |
Erasca, Inc. 3115 Merryfield Row, Suite 300 San Diego, CA 92121 Erasca, Inc. 3115 Merryfield Row, Suite 300 San Diego, CA 92121 May 14, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Erasca, Inc. Registration Statement on Form S-3 File No. 333-279261 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securiti |
|
| May 9, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Erasca, Inc. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Erasca, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par va |
|
| May 8, 2024 |
Exhibit 99.1 Erasca Reports First Quarter 2024 Business Updates and Financial Results Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is ex |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 28, 2024 |
Exhibit 99.1 Erasca Announces $45 Million Oversubscribed Private Placement Financing Funding from new and existing investors extends anticipated cash runway into H2 2026 SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MA |
|
| March 28, 2024 |
Exhibit 10.1 ERASCA, INC. STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of March 27, 2024 (the “Effective Date”), by and between ERASCA, INC., a Delaware corporation (the “Company”), and each of the purchasers whose names are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Purchasers desire to purchase, se |
|
| March 28, 2024 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 27, 2024 |
Erasca, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 Erasca, Inc. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Erasca, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy shall a |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (E |
|
| March 27, 2024 |
Erasca, Inc. Non-Employee Director Compensation Program Exhibit 10.18 Erasca, Inc. Non-Employee Director Compensation Program Updated December 12, 2023 Non-employee members of the board of directors (the “Board”) of Erasca, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, a |
|
| March 27, 2024 |
Exhibit 99.1 Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAF |
|
| February 14, 2024 |
ERAS / Erasca, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-eras123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ERASCA, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29479A108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2024 |
ERAS / Erasca, Inc. / City Hill, LLC - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP |
|
| January 30, 2024 |
ERAS / Erasca, Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 3 Activist Investment SC 13D/A 1 cormorantsc13da.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 8 |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2024 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 9, 2024 |
On a Journey to Erase Cancer Erasca Corporate Presentation January 2024 Exhibit 99. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 28, 2023 | ||
| November 9, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED First Amendment to Exclusive License Agreement This First Amendment to the Exclusive License Agreement (the “First Amendment”) effective as of August 7, 2023 (the “Amendment Effective Date”), is |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| November 9, 2023 |
Erasca Reports Third Quarter 2023 Financial Results and Business Updates First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO, November 9, 2023 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 10, 2023 |
Erasca Reports Second Quarter 2023 Financial Results and Business Updates Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple meaningful clinical catalysts over the next 18 months and beyond Strong balance sheet with cash, cash equivalents, and marketable securities of $365 million as of June 30, 2023, expected to fund operations into H2 2025 SAN DIEGO, August 10, 2023 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| August 10, 2023 |
Exhibit 10.1 April 10, 2023 Shannon Morris, M.D., Ph.D. Re: Amended and Restated Employment Letter Agreement Dear Shannon: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment offer letter, dated as of May 2, 2022 (the “Prior Agreement”), by and between you and Erasca, Inc. (the “Company”). This Agreement will serve to memorialize the |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
On a Journey to Erase Cancer Erasca Investor Presentation June 5, 2023 Exhibit 99. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 15, 2023 |
Exhibit 99.1 Erasca Reports First Quarter 2023 Financial Results and Business Updates Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1 2024; dosing of the first patient in Phase 1b SEACRAFT-1 trial in patients with RAS Q61X tissue agnostic solid tumor |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 04, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 23, 2023 |
Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Execution Copy EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is entered into as of December 9, 2022 (the “Effective Date”) by and between Novartis Pharma AG (“N |
|
| March 23, 2023 |
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials for ERAS-007, ERAS-601, and ERAS-801 Dosing of the first pat |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (E |
|
| February 14, 2023 |
ERAS / Erasca, Inc. / City Hill, LLC - SC 13G/A Passive Investment SC 13G/A 1 d214659dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class o |
|
| February 14, 2023 |
ERAS / Erasca, Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d4sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Erasca, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 29479A108 (CUSIP Number) December 31, 20 |
|
| February 9, 2023 |
Revised Anticipated Key Milestones Slide, dated February 8, 2023 EX-99.1 Exhibit 99.1 Anticipated key milestones - Updated February 8, 2023 Program Trial Name 2023 2024 Mechanism Indication SEACRAFT-1 H2 2023 Q2 2024 – Q4 2024 3 Ph 1b FPD Ph 1b combo data RAS Q61X Solid Tumors Naporafenib Pan-RAF inhibitor SEACRAFT-2 H1 2024 3 Ph 3 pivotal FPD NRASm Melanoma HERKULES-1 H1 2024 4 Ph 1b combo data Advanced Solid Tumors ERAS-007 and/or ERAS-601 HERKULES-2 H1 2023 |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 9, 2023 |
On a Journey to Erase Cancer Erasca Corporate Presentation January 2023 Exhibit 99. |
|
| December 21, 2022 |
ERAS / Erasca, Inc. / Cormorant Asset Management, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 857-702-0386 (Name, Address and Telephone Number |
|
| December 19, 2022 |
EVIDENCE OF SIGNATORY AUTHORITY EXHIBIT 1 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled 1 CHE-106. |
|
| December 19, 2022 |
ERAS / Erasca, Inc. / NOVARTIS PHARMA AG - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 19, 2022 |
EXHIBIT 2 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0. |
|
| December 9, 2022 |
Erasca Announces Pricing of Underwritten Offering of Common Stock Exhibit 99.1 Erasca Announces Pricing of Underwritten Offering of Common Stock December 9, 2022 SAN DIEGO, December 9, 2022 (GLOBE NEWSWIRE) ? Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering |
|
| December 9, 2022 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 9, 2022 |
Exhibit 99.1 On a Journey to Erase Cancer Erasca Corporate Presentation December 2022 Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the anticipated naporafenib licensing transaction and when and whe |
|
| December 9, 2022 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266802 Prospectus supplement (To prospectus dated August 18, 2022) 15,384,616 Shares Common stock We are offering 15,384,616 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ERAS.” On December 8, 2022, the last reported sale price for our common stock on the Nasd |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 9, 2022 |
EX-1.1 2 d435484dex11.htm EX-1.1 Exhibit 1.1 Erasca, Inc. 15,384,616 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement December 9, 2022 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Goldman Sachs & Co. LLC 200 West Street |
|
| November 9, 2022 |
Exhibit 99.1 Erasca Reports Third Quarter 2022 Financial Results and Business Updates Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer to supply palbociclib in combination with ERAS-007; signed strategic R&D collaboration with MD Anderson Strong |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 7, 2022 |
Erasca R&D Day September 2022 Exhibit 99.1 We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of o |
|
| September 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 6, 2022 |
ERAS / Erasca, Inc. / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 29479A108 (CUSIP Number) August 26, 2022 (Date of Event Which Requires Filing of |
|
| September 6, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Erasca, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. |
|
| August 16, 2022 |
Erasca, Inc. 3115 Merryfield Row, Suite 300 San Diego, CA 92121 CORRESP 1 filename1.htm Erasca, Inc. 3115 Merryfield Row, Suite 300 San Diego, CA 92121 August 16, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Erasca, Inc. Registration Statement on Form S-3 File No. 333-266802 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Reg |
|
| August 11, 2022 |
Exhibit 4.4 ERASCA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section 2.2. Establishment of Ter |
|
| August 11, 2022 |
Exhibit 99.1 Erasca Reports Second Quarter 2022 Financial Results and Business Updates Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2 2022 IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C mutant NSCLC in H2 2022 Bolstered clinical, operational, and commercial leadership Strong |
|
| August 11, 2022 |
Open Market Sale Agreement, dated August 11, 2022, by and between Jefferies LLC and the Registrant EX-1.2 2 d354047dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM August 11, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Erasca, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of |
|
| August 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Erasca, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2022 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 29 day of September, 2020, between ARE-SD REGION NO. 23, LLC, a Delaware limited liability company (?Landlord?), and ERASCA, INC |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2022 |
Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership and ERASCA, INC., a Delaware corporation Table of Contents 1. Lease of Premises 2 2. Basic Lease Provisions 3 3. Ter |
|
| May 12, 2022 |
Erasca Reports First Quarter 2022 Financial Results and Business Updates Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Phase 1b monotherapy data for ERAS-007 and Phase 1 monotherapy data for ERAS-601 expected in H2 2022; IND filing for ERAS-3490 on track for H2 2022 Strong balance sheet with cash of $422 million expected to fund operations into H2 2024 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 24, 2022 |
Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership and ERASCA, INC., a Delaware corporation Table of Contents 1. Lease of Premises 2 2. Basic Lease Provisions 3 3. Te |
|
| March 24, 2022 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN KATMAI PHARMACEUTICALS, INC. AND ERASCA, INC. DATED AS OF MARCH 12, 2020 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] |
|
| March 24, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Erasca, Inc. (?we,? ?us? and ?our?) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. Description of Common Stock General The following descript |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (E |
|
| March 24, 2022 |
Exhibit 99.1 Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459 million SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) - Erasca, Inc. |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 18, 2022 |
ERAS / Erasca, Inc. / Colt Ventures, Ltd. - SC 13G Passive Investment SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 29479A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) ? Rule 13d-1(c) ? Ru |
|
| February 14, 2022 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 14, 2022 |
ERAS / Erasca, Inc. / City Hill, LLC - SC 13G Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP Number) D |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 29479A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| November 23, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2021 |
Exhibit 99.1 Erasca Reports Third Quarter 2021 Financial Results and Business Updates Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech?s ?Fierce 15? most promising biotechnology companies of 2021 Donated $17.5 million of common shares to the Erasca Foundation to fund mission-related charitable activ |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Erasca, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40602 83-1217027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 26, 2021 |
Exhibit 99.1 Erasca Reports Second Quarter 2021 Financial Results and Business Updates Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) beginning in 2022 Strengthened executive leadership team with multiple appointments SAN DIEGO, August 26, 2021 (GLOBE NEWSWIRE) ? Erasca, Inc. (Nasdaq: ERAS), a clinical |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40602 ERASCA, INC. |
|
| August 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2021 ERASCA, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 83-1217027 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 10, 2021 |
ERAS / Erasca, Inc. / Cormorant Asset Management, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 857-702-0386 (Name, Address and Telephone Number |
|
| July 30, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 30, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with the |
|
| July 30, 2021 |
ERAS / Erasca, Inc. / Cormorant Asset Management, LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Erasca, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29479A108 (CUSIP Number) Neb Obradovic Cormorant Asset Management, L.P. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Tel. No.: 857-702-0386 (Name, Address and Telephone Number |
|
| July 20, 2021 |
Amended and Restated Certificate of Incorporation of Erasca, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Erasca, Inc. The Corporation was incorporated under the name Erasca, Inc. by the filing of its original Certific |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2021 ERASCA, INC. (Exact name of registrant as specified in its charter) Delaware 001-40602 83-1217027 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| July 20, 2021 |
Amended and Restated Bylaws of Erasca, Inc. Exhibit 3.2 Amended and Restated Bylaws of Erasca, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election to the Board. 5 2 |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 16, 2021 As filed with the Securities and Exchange Commission on July 16, 2021 Registration No. |
|
| July 16, 2021 |
Founder’s letter To Erase cancer: Our mission fuels our journey To bring patients hope. Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257436 18,750,000 shares Common Stock This is the initial public offering of shares of common stock of Erasca, Inc. We are offering 18,750,000 shares of our common stock to be sold in this offering. The initial public offering price is $16.00 per share of common stock. Prior to this offering, there has been no public market fo |
|
| July 15, 2021 |
As filed with the Securities and Exchange Commission on July 15, 2021 S-1MEF 1 d167365ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on July 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Erasca, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 83-1217027 (State or Other Jurisdiction of Incorporatio |
|
| July 13, 2021 |
Erasca, Inc. 10835 Road to the Cure, Suite 140 San Diego, CA 92121 Erasca, Inc. 10835 Road to the Cure, Suite 140 San Diego, CA 92121 July 13, 2021 VIA EDGAR Ms. Tonya K. Aldave Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Erasca, Inc. Registration Statement on Form S-1 File No. 333-257436 Dear Ms. Aldave: Pursuant to Rule 461 of Regulation C of the General Rules and R |
|
| July 13, 2021 |
July 13, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ERASCA, INC. (Exact name of registrant as specified in its charter) Delaware 83-1217027 (State of incorporation or organization) (I.R.S. Employer Identification No.) 10835 Road to the Cure, Suite 1 |
|
| July 12, 2021 |
Exhibit 10.2 ERASCA, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defin |
|
| July 12, 2021 |
Form of Underwriting Agreement EX-1.1 2 d176019dex11.htm EX-1.1 Exhibit 1.1 Erasca, Inc. [•] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement [•], 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Morgan Stanley & Co. LLC 1585 B |
|
| July 12, 2021 |
EX-10.14 11 d176019dex1014.htm EX-10.14 Exhibit 10.14 July 9, 2021 David Chacko, M.D. Re: Amended and Restated Employment Letter Agreement Dear David: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment offer letter, dated as of February 5, 2020 (the “Prior Agreement”), by and between you and Erasca, Inc. (the “Company”). This Agreem |
|
| July 12, 2021 |
Exhibit 10.13 July 9, 2021 Jonathan Lim, M.D. Re: Amended and Restated Employment Letter Agreement Dear Jonathan: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment letter agreement, dated as of February 27, 2020 (the ?Prior Agreement?), by and between you and Erasca, Inc. (the ?Company?). This Agreement will serve to memorialize th |
|
| July 12, 2021 |
Non-Employee Director Compensation Program Exhibit 10.5 ERASCA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Erasca, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically |
|
| July 12, 2021 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: The name of the corporation is Erasca, Inc. The corporation originally filed its Certificate of Incorporation with the Secretary of State of the State of Delaware on July 2, 2018. I. The name of the co |
|
| July 12, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Milan July |
|
| July 12, 2021 |
Form of Indemnification Agreement for Directors and Officers EX-10.17 14 d176019dex1017.htm EX-10.17 Exhibit 10.17 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Erasca, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemn |
|
| July 12, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on July 12, 2021 Registration No. |
|
| July 12, 2021 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Erasca, Inc. The Corporation was incorporated under the name Erasca, Inc. by the filing of its original Certific |
|
| July 12, 2021 |
Exhibit 10.16 July 9, 2021 Ebun Garner Re: Amended and Restated Employment Letter Agreement Dear Ebun: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment letter agreement, dated as of February 27, 2020 (the ?Prior Agreement?), by and between you and Erasca, Inc. (the ?Company?). This Agreement will serve to memorialize the terms of |
|
| July 12, 2021 |
Exhibit 10.15 July 9, 2021 Wei Lin, M.D. Re: Amended and Restated Employment Letter Agreement Dear Wei: This amended and restated employment letter agreement (this ?Agreement?) amends and restates that certain employment offer letter, dated as of November 5, 2020 (the ?Prior Agreement?), by and between you and Erasca, Inc. (the ?Company?). This Agreement will serve to memorialize the terms of your |
|
| July 12, 2021 |
Erasca, Inc. Severance and Change in Control Severance Plan and Summary Plan Description Exhibit 10.4 ERASCA, INC. SEVERANCE AND CHANGE IN CONTROL SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Erasca, Inc. Severance and Change in Control Severance Plan (the ?Plan?) is to provide assurances of specified severance benefits to eligible employees of the Company whose employment is subject to being involuntarily terminated by the Company other than for Ca |
|
| July 12, 2021 |
Erasca, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.3 ERASCA, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to qualify as an |
|
| June 28, 2021 |
CORRESP 1 filename1.htm 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York FOIA CONFIDENTIAL TREATMENT REQUEST Century City Orange County Chicago Paris The entity requesting confidential treatment is: Dubai Riyadh Düsseldorf Rome Frankfurt San Diego Erasca, Inc. Hamburg San |
|
| June 25, 2021 |
Exhibit 10.10 ERASCA, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2020 (the “Effective Date”), by and between ERASCA, INC., a Delaware corporation (the “Company”), having its principal place of business at 10835 Road to the Cure, Suite 140, San Diego, CA 92121, and MICHAEL D. VARNEY, PH.D., an indivi |
|
| June 25, 2021 |
Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 29 day of September, 2020, between ARE-SD REGION NO. 23, LLC, a Delaware limited liability company (“Landlord”), and ERASCA, IN |
|
| June 25, 2021 |
EX-10.6 Exhibit 10.6 February 27, 2020 Jonathan Lim, M.D. Re: Employment Letter Agreement Dear Jonathan: This letter will serve to memorialize the terms of your continued employment with Erasca, Inc. (the “Company”) as provided in this employment letter agreement (this “Agreement”), effective from and after January 1, 2020. • DUTIES. You will serve as the Chairman of the Board of Directors of the |
|
| June 25, 2021 |
Exhibit 4.2 ERASCA, INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of April 15, 2020, by and among Erasca, Inc., a Delaware corporation (the “Company”), and the investors set forth on Schedule A hereto (each, an “Investor”). WHEREAS, the Company and certain of the Investors are parties to the Series B Preferred Stock |
|
| June 25, 2021 |
Specimen stock certificate evidencing the shares of common stock EX-4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# Exhibit 4.1 COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 43 2 1 A BOX DESIGNATION SAMPLE Certificate Shares 505006, Number * * 000000 ****************** (IF * * * 000000 ***************** ANY) ZQ00000000 **** 000000 **************** Louisville, ERASCA, INC. ***** 000000 *************** KY ****** 000000 ************** I |
|
| June 25, 2021 |
EX-3.2 Exhibit 3.2 BYLAWS OF ERASCA, INC. (a Delaware corporation) Adopted as of July 2, 2018 TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. PLACE OF KEEPING CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1. ANNUAL MEETING 1 SECTION 2. SPECIAL MEETING 1 SECTION 3. |
|
| June 25, 2021 |
Release Agreement, dated December 15, 2020, by and between Gary Yeung and the Registrant Exhibit 10.8 GENERAL RELEASE OF CLAIMS THIS GENERAL RELEASE OF CLAIMS (this “Release”) is entered into by and between Erasca, Inc., a Delaware corporation (the “Company”), and Gary Yeung, MBA, CFA (“Employee”), as of the Effective Date (as defined below). WHEREAS, Employee’s employment with the Company will terminate effective December 15, 2020 (the “Separation Date”); WHEREAS, the parties agree t |
|
| June 25, 2021 |
Exhibit 10.1 ERASCA, INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning the interests |
|
| June 25, 2021 |
Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this ?Agreement?), dated as of November 23, 2020, is entered into among (i) ERASCA, INC., a Delaware corporation (?Parent?), (ii |
|
| June 25, 2021 |
Employment Letter Agreement, dated March 27, 2021, by and between Ebun S. Garner and the Registrant Exhibit 10.12 March 27, 2021 Ebun Garner Re: Employment Offer Letter Dear Ebun: Erasca, Inc. (the “Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”). • DUTIES. You shall serve and shall perform such duties as are customarily associated with the position of General Counsel, and such other duties as are assigned to you by your supervisor. You will |
|
| June 25, 2021 |
Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) dated as of February 18, 2020 (the ?Effective Date?), is entered into between Erasca, Inc., a Delaware corporation (?Erasca?), havin |
|
| June 25, 2021 |
Amended and Restated Certificate of Incorporation, as amended Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Erasca, Inc. The Corporation was incorporated under the name Erasca, Inc. by the filing of its original Certific |
|
| June 25, 2021 |
EX-3.4 5 d176019dex34.htm EX-3.4 Exhibit 3.4 Amended and Restated Bylaws of Erasca, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominatio |
|
| June 25, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com June 25, 2021 VIA EDGAR Ms. Tonya K. Aldave Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 FIRM /AFFILIATE OFFICES Beijing Boston Brussels Century City Chicago Dubai D?sseldorf Frankfurt Hamburg Hong Kong H |
|
| June 25, 2021 |
Exhibit 10.22 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN KATMAI PHARMACEUTICALS, INC. AND ERASCA, INC. DATED AS OF MARCH 12, 2020 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] |
|
| June 25, 2021 |
Exhibit 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is entered into as of March 12, 2021 (the “Effective Date”) by and between Erasca, Inc., a Delaware c |
|
| June 25, 2021 |
Exhibit 10.7 February 5, 2020 David Chacko Re: Restated Employment Offer Letter Dear David: You are currently a party to an employment offer letter with Erasca, Inc. (the “Company”) dated April 19, 2019 (the “Original Agreement”). You and the Company hereby agree to amend and restate the Original Agreement to add certain severance benefits, as provided in this amended employment offer letter (this |
|
| June 25, 2021 |
EX-10.9 Exhibit 10.9 August 18, 2020 Via Email Michael D. Varney, Ph.D. Re: Chairman of R&D Agreement Dear Dr. Varney: Erasca, Inc. (the “Company”) is pleased to offer you employment as Chairman of R&D, reporting to Dr. Jonathan Lim. • DUTIES. In your position as Chairman of R&D, you will have the powers, duties, responsibilities, and accountabilities as set forth below and in the job description |
|
| June 25, 2021 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: The name of the corporation is Erasca, Inc. The corporation originally filed its Certificate of Incorporation with the Secretary of State of the State of Delaware on July 2, 2018. I. The name of |
|
| June 25, 2021 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED LICENSE AGREEMENT This AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is made as of November 23, 2020 (the “Effective Date”), by and between ASANA BIOSCIENCES, |
|
| June 25, 2021 |
Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended EX-10.19 17 d176019dex1019.htm EX-10.19 Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership and ERASCA, INC., a Delaware corporation Table of Contents 1. Lease of Prem |
|
| June 25, 2021 |
Employment Letter Agreement, dated November 5, 2020, by and between Wei Lin, M.D. and the Registrant EX-10.11 Exhibit 10.11 November 5, 2020 Wei Lin, M.D. Re: Employment Offer Letter Dear Wei: Erasca, Inc. (the “Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”). • DUTIES. You shall serve and shall perform such duties as are customarily associated with the position of Chief Medical Officer, and such other duties consistent with such position as a |
|
| June 25, 2021 |
Licence Agreement, dated April 16, 2020, by and between LifeArc and the Registrant Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENCE AGREEMENT Between LIFEARC and ERASCA, INC. TABLE OF CONTENTS 1. Definitions and Interpretation 1 2. Grant of Rights 7 3. Know-how and other Confidential Information 10 4. Payments 11 5 |
|
| June 25, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on June 25, 2021 Registration No. |
|
| June 25, 2021 |
EX-10.20 18 d176019dex1020.htm EX-10.20 Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and ERASCA, INC for Novel Covalent Inhibitors of GTP and GDP-bound RAS U |
|
| June 9, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Milan June |
|
| June 9, 2021 |
EX-10.17 Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN KATMAI PHARMACEUTICALS, INC. AND ERASCA, INC. DATED AS OF MARCH 12, 2020 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED |
|
| June 9, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 9, 2021 as Amendment No. |
|
| May 7, 2021 |
ERASCA, INC. 2018 EQUITY INCENTIVE PLAN EX-10.1 5 filename5.htm Exhibit 10.1 ERASCA, INC. 2018 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better |
|
| May 7, 2021 |
EX-10.13 13 filename13.htm Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 29 day of September, 2020, between ARE-SD REGION NO. 23, LLC, a Delaware limited liability company ( |
|
| May 7, 2021 |
EX-10.15 15 filename15.htm Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and ERASCA, INC for Novel Covalent Inhibitors of GTP and GDP-bound RAS UC Case No. SF |
|
| May 7, 2021 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ERASCA, INC. EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ERASCA, INC. Erasca, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: The name of the corporation is Erasca, Inc. The corporation originally filed its Certificate of Incorporation with the Secretary of State of the State of Delaware on July 2, 2018 |
|
| May 7, 2021 |
EX-10.8 9 filename9.htm Exhibit 10.8 August 18, 2020 Via Email Michael D. Varney, Ph.D. Re: Chairman of R&D Agreement Dear Dr. Varney: Erasca, Inc. (the “Company”) is pleased to offer you employment as Chairman of R&D, reporting to Dr. Jonathan Lim. • DUTIES. In your position as Chairman of R&D, you will have the powers, duties, responsibilities, and accountabilities as set forth below and in the |
|
| May 7, 2021 |
ERASCA, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT EX-10.9 10 filename10.htm Exhibit 10.9 ERASCA, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (this “Agreement”) is made and entered into as of August 15, 2020 (the “Effective Date”), by and between ERASCA, INC., a Delaware corporation (the “Company”), having its principal place of business at 10835 Road to the Cure, Suite 140, San Diego, CA 92121, and MICHAEL D. |
|
| May 7, 2021 |
AMENDED AND RESTATED LICENSE AGREEMENT EX-10.20 20 filename20.htm Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL Execution Version AMENDED AND RESTATED LICENSE AGREEMENT This AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is made as of November 23, 2020 |
|
| May 7, 2021 |
EX-10.5 Exhibit 10.5 February 27, 2020 Jonathan Lim, M.D. Re: Employment Letter Agreement Dear Jonathan: This letter will serve to memorialize the terms of your continued employment with Erasca, Inc. (the “Company”) as provided in this employment letter agreement (this “Agreement”), effective from and after January 1, 2020. • DUTIES. You will serve as the Chairman of the Board of Directors of the |
|
| May 7, 2021 |
EX-10.14 14 filename14.htm Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE by and between BMR-ROAD TO THE CURE LP, a Delaware limited partnership and ERASCA, INC., a Delaware corporation Table of Contents 1. Lease of Premises 2 2. Bas |
|
| May 7, 2021 |
BYLAWS ERASCA, INC. (a Delaware corporation) Adopted as of July 2, 2018 EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF ERASCA, INC. (a Delaware corporation) Adopted as of July 2, 2018 TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. PLACE OF KEEPING CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1. ANNUAL MEETING 1 SECTION 2. SPECIAL MEETI |
|
| May 7, 2021 |
LICENCE AGREEMENT ERASCA, INC. Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENCE AGREEMENT Between LIFEARC and ERASCA, INC. TABLE OF CONTENTS 1. Definitions and Interpretation 1 2. Grant of Rights 7 3. Know-how and other Confidential Information 10 4. Payments 11 5 |
|
| May 7, 2021 |
EX-10.17 17 filename17.htm Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN KATMAI PHARMACEUTICALS, INC. AND ERASCA, INC. DATED AS OF MARCH 12, 2020 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THI |
|
| May 7, 2021 |
ERASCA, INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENT EX-4.2 4 filename4.htm Exhibit 4.2 ERASCA, INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of April 15, 2020, by and among Erasca, Inc., a Delaware corporation (the “Company”), and the investors set forth on Schedule A hereto (each, an “Investor”). WHEREAS, the Company and certain of the Investors are parties to the S |
|
| May 7, 2021 |
EX-10.21 Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is entered into as of March 12, 2021 (the “Effective Date”) by and between Erasca, Inc., a D |
|
| May 7, 2021 |
EX-10.16 16 filename16.htm Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”) dated as of February 18, 2020 (the “Effective Date”), is entered into between Erasca, Inc., a Delaware co |
|
| May 7, 2021 |
EX-10.7 8 filename8.htm Exhibit 10.7 GENERAL RELEASE OF CLAIMS THIS GENERAL RELEASE OF CLAIMS (this “Release”) is entered into by and between Erasca, Inc., a Delaware corporation (the “Company”), and Gary Yeung, MBA, CFA (“Employee”), as of the Effective Date (as defined below). WHEREAS, Employee’s employment with the Company will terminate effective December 15, 2020 (the “Separation Date”); WHER |
|
| May 7, 2021 |
Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this ?Agreement?), dated as of November 23, 2020, is entered into among (i) ERASCA, INC., a Delaw |
|
| May 7, 2021 |
Exhibit 10.11 March 27, 2021 Ebun Garner Re: Employment Offer Letter Dear Ebun: Erasca, Inc. (the ?Company?) is pleased to offer you a position on the terms set forth in this letter (this ?Agreement?). ? DUTIES. You shall serve and shall perform such duties as are customarily associated with the position of General Counsel, and such other duties as are assigned to you by your supervisor. You will |
|
| May 7, 2021 |
EX-10.6 Exhibit 10.6 February 5, 2020 David Chacko Re: Restated Employment Offer Letter Dear David: You are currently a party to an employment offer letter with Erasca, Inc. (the “Company”) dated April 19, 2019 (the “Original Agreement”). You and the Company hereby agree to amend and restate the Original Agreement to add certain severance benefits, as provided in this amended employment offer lett |
|
| May 7, 2021 |
Exhibit 10.10 November 5, 2020 Wei Lin, M.D. Re: Employment Offer Letter Dear Wei: Erasca, Inc. (the ?Company?) is pleased to offer you a position on the terms set forth in this letter (this ?Agreement?). ? DUTIES. You shall serve and shall perform such duties as are customarily associated with the position of Chief Medical Officer, and such other duties consistent with such position as are assign |
|
| May 7, 2021 |
As confidentially submitted to the Securities and Exchange Commission on May 7, 2021 Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 7, 2021 Registration No. |
